Supernus Pharmaceuticals (NASDAQ:SUPN) is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system (CNS) disorders. Headquartered in Rockville, Maryland, Supernus concentrates on branded therapies for conditions such as epilepsy, attention-deficit/hyperactivity disorder (ADHD), migraine and Parkinson’s disease. Since its inception in 2008, the company has built a portfolio of extended‐release formulations and novel drug delivery technologies aimed at improving patient outcomes and adherence.
The company’s marketed products include Trokendi XR® and Oxtellar XR® for epilepsy, Qelbree® (viloxazine hydrochloride) for ADHD in children and adults, and Xadago® (safinamide) for Parkinson’s disease. Supernus invests in research and development to advance its pipeline, which encompasses both next‐generation formulations of existing therapies and new molecular entities designed to address unmet needs in neurology. Collaborations with academic institutions and contract research organizations support the company’s efforts to expand its clinical programs.
Supernus went public in 2013 and has grown its commercial infrastructure primarily across the United States. The company leverages strategic partnerships to distribute certain products internationally, enhancing its global reach. Supernus is known for its patient‐centric approach, offering support programs that provide education, reimbursement assistance and other resources to individuals and caregivers managing chronic CNS conditions.
Under the leadership of President and Chief Executive Officer Suvarna Patel and a seasoned executive team, Supernus continues to refine its strategic focus on neuroscience. The board of directors and senior management bring extensive experience in pharmaceutical development, regulatory affairs and commercialization, positioning the company for sustained growth in the CNS therapeutic area.
